作者
Deepak L Bhatt, Keith AA Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel Steg, Steven R Steinhubl, Michael A Weber, Danielle M Brennan, Liz Fabry-Ribaudo, Joan Booth, Eric J Topol
发表日期
2006/4/20
期刊
New England Journal of Medicine
卷号
354
期号
16
页码范围
1706-1717
出版商
Massachusetts Medical Society
简介
Background
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
Methods
We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes.
Results
The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent …
引用总数
学术搜索中的文章
DL Bhatt, KAA Fox, W Hacke, PB Berger, HR Black… - New England Journal of Medicine, 2006
DL Bhatt, KA Fox, W Hacke, PA Berger, HR Black… - Clopidogrel and aspirin versus aspirin alone for the …, 2006